<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Survival of patients with <z:e sem="disease" ids="C1136084" disease_type="Neoplastic Process" abbrv="">plasma cell disorders</z:e> has increased </plain></SENT>
<SENT sid="1" pm="."><plain>However, the expanding use of melphalan in patients with longer survival suggests that <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> may become increasingly important </plain></SENT>
<SENT sid="2" pm="."><plain>The objective of this study was to determine the risk of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> after treatment with melphalan for patients with <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We reviewed the long-term follow-up data (more than 12 years) from 101 patients with immunoglobulin light-chain <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>We identified 10 patients with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> or <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> that directly caused <z:hpo ids='HP_0011420'>death</z:hpo> for 8 and transfusion dependency for 2 </plain></SENT>
<SENT sid="5" pm="."><plain>Two of the 10 patients did not have development of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> until 144 months after first exposure to <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>The actuarial risk of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> development at ten years was 18% </plain></SENT>
<SENT sid="7" pm="."><plain>As the survival of patients with <z:e sem="disease" ids="C1136084" disease_type="Neoplastic Process" abbrv="">plasma cell disorders</z:e> improves, <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> may be a more common cause of morbidity and mortality for this group </plain></SENT>
</text></document>